Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Accenture
Chinese Patent Office
Baxter
Boehringer Ingelheim
Deloitte
McKesson
UBS
Johnson and Johnson

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,420,057

« Back to Dashboard

Which drugs does patent 7,420,057 protect, and when does it expire?

Patent 7,420,057 protects ADDYI and is included in one NDA.

This patent has thirty-five patent family members in thirty countries.
Summary for Patent: 7,420,057
Title:Stable polymorph of flibanserin
Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.
Inventor(s): Bombarda; Carlo (Chester, VA), Dubini; Enrica (Milan, IT), Ezhaya; Antoine (Milan, IT), Schneider, legal representative; Margarete (Ingelheim, DE), Schneider; Heinrich (Ingelheim, DE)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:11/546,304
Patent Claim Types:
see list of patent claims
Compound; Composition; Process;

Drugs Protected by US Patent 7,420,057

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,420,057

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01118593Aug 2, 2001
01130180Dec 19, 2001

Non-Orange Book US Patents Family Members for Patent 7,420,057

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,183,410 Stable polymorph of flibanserin ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,420,057

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 76767 ➤ Try a Free Trial
Slovenia 1414816 ➤ Try a Free Trial
Serbia 50742 ➤ Try a Free Trial
Yugoslavia 7804 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Farmers Insurance
Healthtrust
UBS
Chinese Patent Office
QuintilesIMS
Baxter
Argus Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.